N/A
Completed N=1,814
Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea
Source: ClinicalTrials.gov NCT02810509 ↗Enrolled (actual)
1,814
Serious AEs
—
Results posted
Sep 2019
Primary outcomePrimary: Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0. — 43.4; 49.1 percentage of time in therapeutic range
Summary
The current study aims to assess the quality of anticoagulation with warfarin in real world practice of secondary stroke prevention in Korean patients with Atrial fibrillation (AF) and to explore predictors for poor International Normalized Range (INR) control.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time in TTR, the Percentage of Time in the Therapeutic Range of INR Between 2.0-3.0. |
43.4; 49.1 | — |
| SECONDARY Percentage of INR Values in the Therapeutic Range of 2.0-3.0: Numbers of INR Values Within the Therapeutic Range by the Total Numbers of INR Measured. |
3900; 15120 | — |
Eligibility Criteria
Inclusion Criteria
Inclusion criteria for the warfarin-initiated cohort
- Admission due to AF-related ischemic stroke
- Initiation of warfarin therapy and treatment at least for more than 7 days of warfarin adjustment period
- For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
Inclusion criteria for the long-term warfarin-treated cohort
- Admission due to AF-related ischemic stroke
- Long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period
- For TTR calculation, available consecutive INR values ≥3 after the 7 days of warfarin adjustment
- TTR evaluable days ≥ 90 days
Exclusion Criteria
- AF with mechanical valve
- Enrollment in anticoagulation randomized clinical trial
- Enrollment in studies affecting the target INR range.
Data sourced from ClinicalTrials.gov (NCT02810509). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.